

Clinical Trials on Alzheimer's Disease

10th

edition of

Clinical Trials

on Alzheimer's Disease

Preliminary Program

Boston, November 1-4, 2017

LATE CALL
FOR ABSTRACTS
September 1-15, 2017


www.ctad-alzheimer.com

www.ctad-alzheimer.com



BOSTON, USA

Welcome	p. 3
Program	p. 4
- Wednesday, November 1	p. 4
- Thursday, November 2	p. 5
- Friday, November 3	p. 8
- Saturday, November 4	p. 10
Registration/Accommodations	p. 12



Scientific Committee

Susan ABUSHAKRA (San Francisco)
 Paul AISEN (San Diego)
 Kaj BLENNOW (Molndal)
 Merce BOADA (Barcelona)
 Maria CARRILLO (Chicago)
 Mony John DE LEON (New York)
 Rachelle DOODY (Basel)
 Bruno DUBOIS (Paris)
 Howard FELDMAN (San Diego)
 Nick FOX (London)
 Giovanni B. FRISONI (Brescia, Geneva)
 Lutz FROELICH (Mannheim)
 Serge GAUTHIER (Montreal)
 Ezio GIACOBINI (Geneva)
 Michael GRUNDMANN (San Diego)
 Harald HAMPEL (Paris)
 Takeshi IWATSUBO (Tokyo)
 Ara KHACHATURIAN (Washington DC)
 Zaven KHACHATURIAN (Washington DC)
 Virginia LEE (Philadelphia)
 Constantine G. LYKETSOS (Baltimore)
 José Luis MOLINUEVO (Barcelona)
 Jean-Marc ORGOGOZO (Bordeaux)
 Ronald PETERSEN (Rochester)
 Craig W. RITCHIE (Edinburgh)
 Augustin RUIZ (Barcelona)
 Robert RISSMAN (San Diego)
 Stephen SALLOWAY (Providence)
 Philip SCHELTENS (Amsterdam)
 Lon SCHNEIDER (Los Angeles)
 Eric SIEMERS (Philadelphia)
 Peter SNYDER (Rhode Island)
 Reisa SPERLING (Boston)
 Yaakov STERN (New York)
 Jacques TOUCHON (Montpellier)
 John TROJANOWSKI (Philadelphia)
 Bruno VELLAS (Toulouse)
 Michael W. WEINER (San Francisco)
 Gordon WILCOCK (Oxford)
 Bengt WINBLAD (Stockholm)

Dear Colleague,

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today's worldwide leaders in the treatment of Alzheimer's disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

At CTAD 2017 several teams will report the results of their preclinical, Phase II and Phase III trials. This sharing of experiences converges towards a same goal : overcoming the hurdles and speed the development of effective treatments in AD.

We look forward to welcoming you to Boston this November !

Jacques Touchon MD, PhD
 University
 Hospital of Montpellier
 France

Paul Aisen MD
 Alzheimer's
 Therapeutic Research Institute (ATRI)
 University of Southern California (USC),
 San Diego, USA

Bruno Vellas MD, PhD
 University
 Hospital of Toulouse
 France

Mike Weiner MD
 University of California
 San Francisco (UCSF)
 USA



Wednesday, November 1

4:00 – 4:30 p.m.

Welcome from the Organizing Committee and Presentation of the CtaD Lifetime Achievement Award to Prof. Bruno Dubois
Jacques Touchon, Paul Aisen, Bruno Vellas, Mike Weiner

4:30 – 5:00 p.m.

Keynote 1
The Evolution of Preclinical Alzheimer's disease : Implications for Prevention Trials

Reisa Sperling, MD

Professor of Neurology, Harvard Medical School

Director, Center for Alzheimer Research and Treatment

Brigham and Women's Hospital and Massachusetts General Hospital Memory Disorders Unit Boston, USA

5:00 – 6:00 p.m.

Symposium 1
Importance of Serotonin in Alzheimer's Disease Psychosis and the Potential Role of Pimavanserin

Moderator : Jeffrey Cummings,

MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

1. Role of 5-HT_{2a} Receptors in the Pharmacology of Alzheimer's disease Psychosis

Stephen M. Stahl, MD, PhD¹, Ethan S. Burstein, PhD²

(1) University of California, San Diego, CA, USA ; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

2. Clinical Trial of Pimavanserin in Alzheimer's disease Psychosis

Clive Ballard, MBChB, MRCPsych¹, Carol Banister, MBChB, MRCPsych², Jim Youakim, MD³, Bruce Coate, MPH³, Srdjan Stankovic, MD, MSPH³, on behalf of the ADP Investigators

(1) University of Exeter Medical School, Exeter, UK ; (2) King's College, London, UK ; (3) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

3. Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer's disease Psychosis Trials

Pierre N. Tariot, MD¹, Randall Owen, MD², Doral Fredericks, PharmD, MBA²

(1) Banner Alzheimer's Institute and University of Arizona College of Medicine, Phoenix, AZ, USA ; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

Thursday, November 2

8:30 – 10:00 a.m.

Oral Communications

OC1 - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer's Disease of LM11A-31-BHS p75 neurotrophin receptor ligand.

Frank M. Longo, MD, PhD¹, Manfred Windisch, PhD², Niels Andreasen, MD³, Agneta Nordberg, MD, PhD⁴

(1) Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA ; (2) NeuroScios, GmbH, Graz, Austria ; (3) Department of Neurobiology, Karolinska Institute, Stockholm, Sweden ; (4) Center for Alzheimer's Research, Karolinska Institute, Stockholm, Sweden

OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly

Bernard Hanseeuw^{1,2}, Beth Mormino³, Alex Becker¹, Aaron Schultz³, Jorge Sepulcre¹, Kathryn Papp^{3,4}, Heidi Jacobs¹, Jasmeeer Chhatwal³, Dorene Rentz^{3,4}, Reisa Sperling^{3,4}, and Keith Johnson^{1,3,4}

(1) Department of Radiology, Massachusetts General Hospital, Boston, MA, USA ; (2) Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium ; (3) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (4) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

OC3 - Clinical evaluation of ¹⁸F-PI-2620, a next generation TAU PET agent in subject with alzheimer disease and progressive supranuclear PALS

Andrew Stephens¹, John Seiby², Andre Mueller¹, Olivier Barret², Mathias Berndt¹, Jennifer Madonia², David Alagille², Hanno Schieferstein¹, Heiko Kroth³, Santiago Bullich¹, Andrea Pfeifer³, Andreas Muhs³, Gilles Tamagnan², Kenneth Marek², Ludger Dinkelborg¹

(1) Piramal Imaging, Berlin, Germany, (2) Molecular Neuroimaging, New Haven, USA, (3) AC Immune SA, Lausanne, Switzerland

OC4 - Optimizing the Preclinical Alzheimer's Cognitive Composite (PACC) with Semantic Processing : The PACC 5

Kathryn V. Papp, PhD^{1,2}, Dorene M. Rentz, PsyD^{1,2}, Irina Orlovsky, MA¹, Reisa A. Sperling, MD^{1,2}, Elizabeth C. Mormino, PhD^{2,3}

(1) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA ; (2) Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA ; (3) Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, USA

OC5 - Can IT Help with the Screening for Alzheimer's Disease Trials ? From EHR to Web-Based Cognitive Tests and e-Consent.

Michael W. Weiner, MD¹, Peter Schueler, MD^{2,3}, J. Wesson Ashford, MD, PhD^{4,5,6}, Bruno Vellas, MD, PhD^{7,8}

(1) UCSF, San Francisco, USA ; (2) ICON, Langen, Germany ; (3) University Duisburg-Essen, Germany ; (4) Stanford/VA Alzheimer's Disease and Aging Clinical Research Centers, CA, USA ; (5) VA Palo Alto Health Care System, CA, USA ; (6) Stanford University, CA, USA ; (7) University Hospital's Department of Internal Medicine and Clinical Gerontology, Toulouse, France ; (8) Toulouse Gerontopôle, Toulouse, France.

OC6 - Amyloid Beta Oligomers in Alzheimer's Disease: a Missing Piece of the Alzheimer's Puzzle

Jeffrey Cummings, MD¹, Sandrine Andrieu, MD, MPH², Philip Scheltens, MD, PhD³, Kaj Blennow, MD, PhD⁴, Petr Kocis, PhD⁵, John A. Hey, PhD⁵, A. Power, MD⁵, Martin Tolar, MD, PhD⁵, Susan Abushakra, MD⁵

(1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada ; (2) University of Toulouse, Toulouse, France ; (3) VU University Medical Center, Amsterdam, Netherlands ; (4) The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden ; (5) Alzheon, Inc., Boston, MA, USA

10:00 – 10:30 a.m.

Coffee Break and Poster Session

10:30 – 11:30 a.m.

Oral Communications

OC7 - ABBV-8E12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer's Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

Kumar Budur¹, Hana Florian¹, Deli Wang¹, Weining Robieson¹, Holly Soares¹, Joel B. Braunstein², David M. Holtzman³, Randall J. Bateman³, Beatrice Rendenbach-Mueller⁴, Nuno Mendonca¹

(1) AbbVie Inc, North Chicago, IL, USA ; (2) C2N Diagnostics LLC, Saint Louis, MO, USA ; (3) Washington University, St. Louis, MO, USA ; (4) AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring

Maryam Shoai, PhD¹, Richard Pither, PhD², Valentina Escott-Price, PhD³, Simon M Laws, PhD⁴, Harald Hampel, MD, PhD⁵, Simone Lista, PhD⁵, Rik Vandenberghe⁶, Isabelle Cleynen⁶, David Irwin, MD⁷, Vivian Van Deerlin, MD⁸, Greg Davidson, PhD⁹, Virginia M.-Y. Lee, PhD¹⁰, John Q. Trojanowski, MD, PhD¹⁰, John Hardy, PhD DSc¹

(1) UCL Institute of Neurology, London, United Kingdom ; (2) Cytox Ltd, UK, Oxford, United Kingdom ; (3) Cardiff University, Cardiff, United Kingdom ; (4) Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia ; (5) AXA Research Fund & UPMC Chair, Paris, France ; (6) Katholieke Universiteit Leuven, Leuven, Belgium ; (7) Hospital of the University of Pennsylvania, Department of Neurology, University of Pennsylvania, Philadelphia ; (8) Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia ; (9) Ledcourt Associates, UK ; (10) Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia

Thursday, November 2

OC9 - Objective Cognitive Decline in Preceding Years Relates to Self-Report on the Cognitive Function Index in the Harvard Aging Brain Study

Rebecca E. Amariglio PhD^{1,2,3}, Rachel F. Buckley PhD^{2,3,4,5}, Elizabeth C. Mormino PhD^{2,3}, Dylan R. Kim MPH², Gad A. Marshall MD^{1,2,3}, Keith A. Johnson MD^{1,2,3}, Dorene M. Rentz PsyD^{1,2,3}, Reisa A. Sperling MD^{1,2,3}

(1) Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA ; (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (3) Harvard Medical School, Boston, MA, USA ; (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia ; (5) Melbourne School of Psychological Science, University of Melbourne, Australia

OC10 - The Generation Program : Evaluating CNP520 Efficacy in Preclinical Alzheimer's Disease

Cristina Lopez Lopez, MD, PhD¹, Pierre N. Tariot, MD², Angelika Caputo, PhD¹, Fonda Liu, Pharm.D¹, Marie-Emmanuelle Riviere, PhD¹, Marie-Laure Rouzade-Dominguez, PhD¹, Ronald G. Thomas, PhD³, Jessica B. Langbaum, PhD², Rob Lenz, MD, PhD⁴, Eric M. Reiman, MD, PhD², Ana Graf, MD¹.

(1) Novartis Pharma, Basel, Switzerland ; (2) Banner Alzheimer's Institute, Phoenix, AZ, USA ; (3) University of California-San Diego, San Diego, CA, USA ; (4) Amgen, Thousand Oaks, CA, USA.

11:30 – 12:30 p.m.

Symposium 2

CTAD 2017 Statistical Workshop : Estimands and Primary Analyses in AD Clinical Trials

Moderator : Hong Liu-Seifert Ph.D.

Eli Lilly and Company, Indianapolis, IN USA

Fabian Model Ph.D.

Roche, Basel Switzerland

Paul Aisen M.D.

Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

12:30 – 1:30 p.m.

Lunch and Poster Session

1:30 – 2:30 p.m.

Oral Communications

OC11 - A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 (abeotaxane) in Patients with Primary Four Repeat Tauopathies : Corticobasal Syndrome or Progressive Supranuclear Palsy; or the Secondary Tauopathy, Alzheimer's Disease.

Adam Boxer, MD, PhD¹; Zachary Miller, MD¹; Richard Tsai, MD, MBA¹; Mary Koestler, RN, PhD¹; Julio Rojas, MD, PhD¹; Peter Ljubenkov, MD¹; Howie Rosen, MD¹; Gil Rabinovici, MD¹; Anne Fagan-Niven, PhD²; Yann Cobigo, PhD¹; June Jung, PhD¹; Phi Luong, BS¹; Emmeline Chuu, BA¹; Ryan Powers, BA¹; Paige Mumford, BA¹; Bruce Miller, MD¹; Erik Roberson, MD, PhD³

(1) Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA ; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA ; (3) Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA

OC12 - High dose B Vitamin therapy selectively improves cognitive function indicative of cerebrovascular status in the randomized FAVORIT Ancillary Cognitive Trial

Tammy M. Scott^{1,2}, Aron M. Troen^{1,3}, Irwin H. Rosenberg^{1,2}

(1) Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston MA ; (2) Friedman School of Nutrition Science and Policy, Tufts University, Boston MA; (3) Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel

Thursday, November 2

OC13 - Investigational New Alzheimer's Drug Tricaprilin: Results of a Phase 3 Study in Mild-to-Moderate Alzheimer's Disease Patients

Samuel Henderson, PhD¹, Michael Gold, MD², Judith Walker, MD¹, Sabrina Greer¹, Janet Vogel¹, Aaron Shenkin¹
(1) Accera Inc, Boulder, CO, USA ; (2) PPD Inc, Wilmington, NC, USA

OC14 - Characterization of the selective in vivo and in vitro binding properties of crenezumab : insights into crenezumab's unique mechanism of action

William J. Meilandt¹, Janice A. Maloney¹, Jose Imperio¹, Travis W. Bainbridge², Mike Reichelt³, Danielle Mandikian⁴, Yanmei Lu⁵, James A. Ernst², Reina N. Fuji⁶, Jasvinder K. Atwal¹

(1) Department of Neuroscience, Genentech, South San Francisco, CA, USA ; (2) Department of Protein Sciences, Genentech, South San Francisco, CA, USA ; (3) Department of Research Pathology, Genentech, South San Francisco, CA, USA ; (4) Department of Preclinical and Translational Pharmacology, Genentech, South San Francisco, CA, USA ; (5) Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA ; (6) Department of Safety Assessment, Genentech, South San Francisco, CA, USA

2:30 – 3:00 p.m.

Keynote 2

From Academy to Industry: Perspectives for Drug Trials in AD

Rachelle Doody, MD, PhD
Global Head of Neurodegeneration PD Neuroscience,
F. Hoffmann-La Roche, Basel, Switzerland

3:00 – 4:00 p.m.

Late Breaking Oral Communications

4:00 – 4:30 p.m.

Coffee Break and Poster Session

4:30 – 5:30 p.m.

Symposium 3

EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer's Disease

Michael Egan, MD¹, James Kost, PhD¹, Pierre N. Tariot, MD², Paul S Aisen, MD³, Jeffrey L. Cummings, MD, ScD⁴, Bruno Vellas, MD, PhD⁵, Yuki Mukai, MD¹, Tiffini Voss, MD¹, Christine Furtek, MS¹, Erin Mahoney, MS¹, Rik Vandenberghe, MD, PhD⁶, Yi Mo, PhD¹, David Michelson, MD¹

(1) Merck & Co., Inc., Kenilworth, NJ, USA; (2) Banner Alzheimer's Institute, Phoenix, AZ, USA; (3) University of Southern California, San Diego, CA, USA; (4) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; (5) Gerontopole, INSERM U 1027, Alzheimers' Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France; (6) University Hospital of Leuven, Leuven, Belgium

Friday, November 3

08:30 – 10:00 a.m.

Oral Communications

OC15 - Long-Term Cognitive Decline in Patients with Alzheimer's Disease in Association with Treatment with Cholinesterase Inhibitors-Data from SveDem, the Swedish Dementia Registry

María Eriksdotter MD, PhD^{1,2}, Sara Garcia-Ptacek MD, PhD^{1,2}, Ingemar Kåreholt PhD^{3,4}, Dorota Religa MD, PhD^{1,5}, Peter Nordström MD, PhD⁶, Anders Wimo MD, PhD^{1,5,7}, Bengt Winblad MD, PhD^{1,5},

(1) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden. ; (2) Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden. ; (3) Aging Research Center, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden ; (4) Institute of Gerontology, School of Health and Welfare, Jönköping University, Jönköping, Sweden. ; (5) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden ; (6) Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden ; (7) The primary Health care of Hudiksvall-Nordanstig, Sweden

OC16 - Selection of Amyloid Positive Pre-Symptomatic Subjects using Automatic Analysis of Neuropsychological and MRI Data for Cost-Effective Inclusion Procedures in Clinical Trials

Manon Ansart, MSc^{1,2}, Stéphane Epelbaum, MD, PhD^{1,2,3}, Olivier Colliot, PhD^{1,2,3,4}, Didier Dormont, MD^{1,2,4}, Bruno Dubois, Prof., MD^{1,3}, Harald Hampel, Prof., MD, PhD^{1,3,5}, Stanley Durrleman, PhD^{2,1}, for the ADNI, and the INSIGHT study group

(1) Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Institut du cerveau et la moelle (ICM) - Hôpital de la Pitié-Salpêtrière, Boulevard de l'hôpital, Paris, France ; (2) Inria Paris, Aramis project-team, Paris, France ; (3) AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Paris, France ; (4) AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neuroradiology, Paris, France ; (5) AXA Research Fund & UPMC Chair, Paris, France

OC17 - Physical Activity and Longitudinal Cognition: Results from the Harvard Aging Brain Study

Hannah M. Klein¹, Dylan R. Kirn, MPH¹, Aaron P. Schultz, PhD^{1,3}, Jennifer S. Rabin, PhD^{3,4}, Rachel Buckley, PhD^{1,3,5,6}, Dorene M. Rentz, PsyD^{1,2}, Kathryn V. Papp, PhD^{1,2}, Keith A. Johnson, MD^{1,2,3}, Reisa A. Sperling, MD MMSc^{1,2,3}, Jasmeer P. Chhatwal, MD, PhD MMSc^{1,2,3}.

(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (2) Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA ; (3) Harvard Medical School, Boston, MA USA ; (4) Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA ; (5) Florey Institutes of Neurosciences and Mental Health, Melbourne, Australia ; (6) Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia

OC18 - Validation of Tau PET Imaging in Alzheimer's Disease and Other Tauopathies

Niklas Mattsson, MD, PhD^{1,2}, Michael Schöll MD, PhD¹, Tomas Ohlsson MD, PhD³, Andreas Hahn MD, PhD⁴, Olof Strandberg MD, PhD¹, Jonas Jögi MD, PhD⁵, Ruben Smith MD, PhD^{1,6}, Oskar Hansson MD, PhD^{1,2}

(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden ; (2) Memory Clinic, Skåne University Hospital, Malmö, Sweden ; (3) Department of Radiation Physics, Skåne University Hospital, Lund, Sweden ; (4) Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria ; (5) Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden ; (6) Department of Neurology, Skåne University Hospital, Lund, Sweden

OC19 - TOMMORROW: A Trial to Delay the Onset of MCI Due to AD and Qualify a Unique Genetic Algorithm Biomarker: Study Update

Kathleen A. Welsh-Bohmer, PhD¹, Brenda L. Plassman, PhD¹, Carl Chiang, PhD², Meredith Culp, BS³, Patrick Harrigan, BChE³, Janet O'Neil, MBA³, Ryan Walter, BS³, Stephen Haneline, MS², Julian Arbuckle, BSc (Hons)², Shyama Brewster, BSc (Hons)², Yuka Maruyama, D.V.M.², Tom Swanson, BSCE, MBA², Dominic Fitzsimmons, BSc (Hons)³, Alexandria S. Atrins, PhD⁴, Sarah Powell, MSW⁴, Richard Keefe, PhD⁴, Craig Metz, PhD², Deborah Yarbrough, MS, MBA³, Daniel K. Burns, PhD², Ann M. Saunders, PhD², Ferenc Martenyi, MD³ for the TOMMORROW study investigators

(1) Department of Psychiatry & Neurology, Duke University, Durham NC, USA ; (2) Zinfandel Pharmaceuticals, Inc., Chapel Hill NC, USA ; (3) Takeda Development Center Americas, Inc., Deerfield, IL, USA ; (4) NeuroCog Trials, Durham, NC, USA

OC20 - Emerging Plasma-Based Therapies for AD

Montse Costa PhD¹, D. Allan Butterfield PhD², Norman Relkin MD, PhD³

(1) Grifols Institute S.A., Parets del Vallès, Spain ; (2) Department of Chemistry, University of Kentucky, Lexington KY, USA ; (3) Relkin Consulting LLC, New Jersey, USA

10:00 – 10:30 a.m.

Coffee Break and Poster Session

10:30 – 11:00 a.m.

Keynote 3 Genetic Aspects In Clinical Trials

John Hardy, Reta Lila Weston Institute of Neurological Studies, University College London, London UK

11:00 – 12:30 p.m.

Oral Communications

OC21 - Cognitive Run-In Periods for Amyloid-Positive Enriched Secondary Prevention Trials.

Andrew J. Aschenbrenner¹, PhD, Jason Hassenstab^{1,2}, PhD, Eric McDade¹, DO, Guoqiao Wang³, PhD, Tammie L.S. Benzinger⁴, MD, PhD, Randall J. Bateman, MD¹, & John C. Morris¹, MD.

(1) Department of Neurology, Washington University in St. Louis ; (2) Department of Psychological and Brain Sciences, Washington University in St. Louis ; (3) Department of Biostatistics, Washington University in St. Louis ; (4) Department of Radiology, Washington University in St. Louis

Friday, November 3

OC22 - Eigen Combinations of Cognition and Biomarkers to Minimize the Sample Sizes in Prevention Trials on Alzheimer Disease

Chengjie Xiong^{1,2,3,4,6}, PhD, Anne M. Fagan^{2,3,6}, PhD, Tammie Benzinger^{2,5,6}, PhD, Jason Hassenstab^{2,3,6}, PhD, John C. Morris^{2,3,6}, MD, Randall J. Bateman^{2,3,6}, MD.

(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA ; (2) Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA ; (3) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA ; (4) Department of Mathematics, Washington University, St. Louis, MO, USA ; (5) Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA ; (6) The Dominantly Inherited Alzheimer Network, Washington University School of Medicine, St. Louis, MO, USA

OC23 - The Alzheimer's Prevention Registry and GeneMatch: Accelerating Recruitment and Enrollment into Alzheimer's Studies

Jessica B. Langbaum, PhD¹, Nellie High¹, David Gordon¹, Jodie Nichols¹, Trisha Walsh¹, Eric M. Reiman¹, MD, Pierre N. Tariot¹, MD

(1) Banner Alzheimer's Institute, Phoenix, AZ, USA

OC24 - An Examination of Rate of Decline as an Alternative to Change from Baseline

Howard Mackey, PhD¹, Nan Hu, PhD¹, Michael Ahmadi, MSc², Yinghua Chen, MSc², Pierre Tariot, MD², Eric M Reiman, MD², Francisco Lopera, MD³, Kewei Chen, PhD², Ronald Thomas, PhD⁴

(1) Genentech, Inc., South San Francisco, CA, USA ; (2) Banner Alzheimer's Institute, Phoenix, AZ, USA ; (3) Universidad de Antioquia, Medellin, Colombia ; (4) UC San Diego Department of Neurosciences, CA, USA

OC25 - The Safety and Efficacy of Edonerpic (T-817) in Patients with Mild to moderate Alzheimer's Disease

Lon S. Schneider, MD¹, Ronald G. Thomas, PhD², James Brewer, MD², Suzanne Hendrix, PhD³, Robert Rissman, PhD², David Salmon, PhD², Hiroshi Kobayashi⁴, Howard Feldman, MD², for the ADCS TCAD group

(1) Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA ; (2) University of California, San Diego, CA, USA ; (3) Pentara Corporation, Salt Lake City, UT, USA ; (4) Toyama Chemical, Ltd, Tokyo, Japan

OC26 - Safety of and Tolerability of Gantenerumab in the Open-Label Extension of SCarlet RoAD Trial, a Global Study in Patients with Prodromal Disease

Mirjana Andjelkovic, PhD¹, Danielle Abi-Saab, Psy.D¹, Nathalie Pross, PhD¹, Paul Delmar, PhD¹, Nicola Voyle, PhD², Michaela Mertes¹, Smiljana Ristic, MD¹

(1) Hoffmann LaRoche, Basel, Switzerland ; (2) Roche Products Limited, Welwyn, UK

12:30 – 1:30 p.m.

Lunch and Poster Session

1:30 – 3:30 p.m.

Late Breaking Oral Communications

3:30 – 4:00 p.m.

Oral Communications

OC27 - The European Prevention of Alzheimer's Dementia (EPAD) and Amyloid Imaging for Prevention of Alzheimer's Dementia (AMYPAD) Projects: Cohort Readiness for the Adaptive Clinical Trial Platform.

Andrew Satlin, MD¹, Craig Ritchie MD PhD², Miia Kivipelto MD PhD², Alina Soloman MD PhD³, Brian Tom PhD⁴, Jose Luis Molinuevo MD PhD⁵, Scott Berry PhD⁶, Frederik Barkhof MD PhD⁷, Gill Farrar PhD⁸

(1) Eisai Pharmaceuticals, USA (2) Centre for Dementia Prevention, University of Edinburgh, UK (3) Ageing Research Centre, Karolinska Institute, Sweden (4) MRC Biostatistics Unit, University of Cambridge, UK (5) Barcelona Beta Brain Research Centre, Spain (6) Berry Consultants Ltd, Texas, USA (7) VU University Medical Centre, Amsterdam, The Netherlands (8) General Electric, Amersham, UK

OC28 - Towards a New Biomarker Battery for Drug Development in Alzheimer's Disease

Olivier Blin, MD, PhD¹, Régis Bordet MD PhD², Jill Richardson PhD³, Pierre Payoux MD PhD⁴, Claudio Babiloni MD PhD⁵, David Bartrés-Faz MD PhD⁶, Catherine Cassé-Perot PhD¹, Giovanni Frisoni MD PhD⁷

(1) University of Aix-Marseille (2) University of Lille (3) GSK (4) University of Toulouse (5) University of Roma (6) University of Barcelona (7) University of Geneva

4:00 – 4:30 p.m.

Coffee Break and Poster Session

4:30 – 5:00 p.m.

Keynote 4

Rationale, Design and Progress of the 3 Active Alzheimer's Prevention Initiative Trials

Pierre Tariot, MD, Banner Alzheimer's Institute, University of Arizona College of Medicine, Phoenix, AZ - USA

5:00 – 6:00 p.m.

Symposium 4

Results from the Phase 3 MINDSET STUDY :

A Global, Double-Blind, Placebo-Controlled Study of Intepirdine in Mild-to-Moderate Alzheimer's Disease

- Presentation 1: Analysis of primary efficacy and safety results
- Presentation 2: Analysis of secondary endpoints and measures of clinical meaningfulness
- Discussion and Q&A

Saturday, November 4

08:30 – 10:00 a.m.

Oral Communications

OC29 - ORY-2001 Rationale in Mild to moderate Alzheimer's Disease

Roger Bullock MD¹, Cesar Molinero MD,PhD¹, Tamara Maes PhD¹

(1) *Oryzon Genomics S.A. Barcelona Spain*

OC30 - Plasma Amyloid Levels within the Alzheimer's Process and Correlations with Central Biomarkers

Olivier Hanon, MD, PhD¹, Jean-Sébastien Vidal MD, PhD¹, Sylvain Lehmann MD, PhD², Stéphanie Bombois MD, PhD³, Bernadette Allinquant MD⁴, Marie Godard Msc¹, Patrick Gelé MD⁵, Christine Delmaire MD³, Frédéric Blanc MD⁶, PhD, S Schraen MD⁵, Audrey Gabelle MD, PhD⁷ and the BALTAZAR study group.

(1) *Department of Gerontology, Broca Hospital, Paris, France*; (2) *Laboratoire de Protéomique Clinique, Department of Biochemistry, Saint Eloi Hospital, IRMB, Inserm U1183, France*; (3) *CMRR de Lille, Department of Neurology, Lille, France*; (4) *Centre de Psychiatrie et Neurosciences, Université Paris Descartes, Paris, France*; (5) *University of Lille Nord de France, Department of Biology and Pathology, Lille University Hospital, INSERM UMR 1172, 59037 Lille, France*; (6) *CMRR de Strasbourg, Department of Gerontology, Strasbourg, France*; (7) *CMRR de Montpellier, Department of Neurology; Inserm U1183, Montpellier, France*.

OC31 - Online Clinical Research: Updates and Insights from the Brain Health Registry

Shannon Finley, MA¹, Diana Truran¹, Derek Flenniken^{1,3}, Juliet Fockler^{1,3}, Rachel L Nosheny PhD^{1,3}, Monica Camacho^{1,3}, R Scott Macrin PhD^{1,2} and Michael W Weiner MD^{1,3}

(1) *Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA*; (2) *UCSF Department of Psychiatry, San Francisco, CA, USA*; (3) *UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA*

OC32 - BPN14770 Phosphodiesterase-4D Negative Allosteric Modulator for Alzheimer's Dementia: Preclinical, PET Imaging and Human Phase 1 Results

Mark Gurney, PhD¹, Chong Zhang PhD², Ying Xu PhD², James O'Donnell PhD², Masahiro Fujita MD, PhD³, Robert Innis MD, PhD³, Victor Pike PhD³, Sanjay Telu PhD³ and Scott Reines, MD, PhD¹

(1) *Tetra Discovery Partners, Inc. Grand Rapids, MI, USA*; (2) *School of Pharmacy and Pharmacological Sciences, University at Buffalo, Buffalo, NY, US*; (3) *National Institute of Mental Health, Bethesda, MD, USA*

OC33 - Amyloid Beta Stable Isotope Labeling Kinetics and Concentrations of Human Plasma Detect CNS Amyloidosis

Vitaliy Ovod MS¹, Kara Ramsey, BS¹, James Bollinger PhD¹, Kwasi Mawuenyega, PhD¹, Terry Hicks, BA¹, Theresa Schneider¹, Thomas Kasten, PhD¹, Wendy Sigurdson, RN¹, Melissa Sullivan, MS¹, Tamara Donahue¹, RN, Katrina Paumier, PhD¹, David Holtzman, MD^{1,2,4}, John Morris, MD^{1,4}, Tammie Benzinger MD, PhD^{2,3}, Anne Fagan PhD^{1,2,4}, Bruce Patterson, PhD⁵, and Randall Bateman, MD^{1,2,4}

(1) *Department of Neurology, Washington University School of Medicine, St Louis, MO*; (2) *Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO*; (3) *Department of Radiology, Washington University School of Medicine, St Louis, MO*; (4) *Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO* (5) *Department of Medicine, Washington University School of Medicine, St Louis, MO*

OC34 - Stereotypical Data-Driven Imaging Biomarker Trajectories across the Alzheimer's Disease Spectrum

Sergey Shcherbinin, PhD¹, Mark A. Mintun, MD², Adam J. Schwarz, PhD¹, For the Alzheimer's Disease Neuroimaging Initiative³

(1) *Eli Lilly and Company, Indianapolis, IN, USA*; (2) *Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA*; (3) *Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu)*

10:00 – 10:30 a.m.

Coffee Break and Poster Session

10:30 – 11:30 a.m.

Late Breaking Oral Communications

11:30 – 12:30 p.m.

Symposium 5

Synaptic and Network Dysfunction in Alzheimer's Disease (AD): Translational Insights and Therapeutic Opportunities

Moderator : Arjen Brussard, PhD, *Amsterdam Neuroscience, VU Medical Center, Amsterdam, Netherlands*

1. Targeting unfolded protein response and synaptic dysfunction to enhance memory function and prevent neurodegeneration

Giovanna Mallucci, MD PhD^{1,2,3}

(1) *Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, UK*; (2) *UK Dementia Research Institute at University of Cambridge, Cambridge, UK* (3) *MRC Toxicology Unit, Leicester, UK*

2. Modulation of synaptic and network activity and endocytosis with light flicker therapy reduces amyloid pathology in mouse model of AD

Li-Hueh Tsai, PhD¹

(1) *Picower Institute of Memory and Learning, Massachusetts Institute of Technology, Cambridge MA, USA*

3. Preclinical rationale and early clinical results of p38 alpha kinase inhibition to reverse hippocampal synaptic dysfunction

John Alam, MD¹

(1) *EIP Pharma, LLC, Cambridge MA, USA*

Saturday, November 4

12:30 – 1:30 p.m.

Lunch and Poster Presentation

1:30 – 2:15 p.m.

Clinical Trials Prescreening Focus Panel : Prescreening Initiatives to Identify Individuals with Preclinical or Early Alzheimer's Disease for Clinical Trials

Moderator : Jamie A Mullen, MD, AstraZeneca, Waltham MA, USA

1. The Funnel study: Prescreening for MCI and mild AD patients from the CHARIOT Register

Geraint J Price, Maxwell J Benjamin, Lisa K Curry, Sabrina WL Smith and Lefros T Middleton
Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, UK

2. A prescreening study using amyloid PET to improve recruitment for early Alzheimer's disease drug trials

Christopher C Rowe, MD Austin Health, Melbourne, Australia

3. Models of Patient Engagement in Alzheimer's Disease (MOPEAD): a European project to move Alzheimer's disease environment towards an earlier diagnosis

Mercè Boada, MD, PhD¹; Laura Campo²; Dhaval Desai³; Hans Peter Hundemer⁴; Octavio Rodríguez-Gómez, MD¹; Bengt Winblad, Prof, MD, PhD⁵; Frank Jessen, MD, PhD⁶; Peter Jelle Visser, MD, PhD⁷; Milica Kramberger, MD, PhD⁸; Rafael Simó, MD, PhD⁹; Rafael Navajo¹⁰; Annette Dumas¹¹; Jean Georges, BA¹²; David Krivec¹³; Peggy Maguire¹⁴; Derek MacKenzie¹⁵

(1) Fundació ACE, Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; (2) Eli Lilly and Company Ltd, Basingstoke, United Kingdom; (3) AstraZeneca AB, Sodertalje, Sweden; (4) Lilly Deutschland GmbH, Bad Homburg, Germany; (5) Karolinska Institutet, Center for Alzheimer Research, Div. of Neurogeriatrics, Huddinge, Sweden; (6) German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany; (7) Stichting VUmc, Amsterdam, Netherlands; (8) University Medical Centre Ljubljana, Ljubljana, Slovenia; (9) Institut de Recerca Hospital Universitari Vall d'Hebron (VHIR), Barcelona, Spain; (10) GMV Soluciones Globales Internet S.A.U., Barcelona, Spain; (11) ASDM Consulting, Auderghem, Belgium; (12) Alzheimer Europe, Luxembourg, Luxembourg; (13) Spomincica – Alzheimer Slovenia, Ljubljana, Slovenia; (14) European Institute of Women's Health, Dublin, Ireland; (15) KITE Innovation (Europe) Ltd, Huddersfield, United Kingdom

2:15 – 3:15 p.m.

Oral Communications

OC35 - Rapid, Remote, and Repeatable: Smartphone-Based "Burst" Cognitive Assessments for Global AD Prevention Trials.

Jason Hassenstab, PhD^{1,2,3,4}, Andrew J. Aschenbrenner, PhD^{1,3,4}, Martin J. Sliwinski, PhD⁴, Eric McDade, DO^{1,3,4}, Yen Ying Lim, PhD⁶, Paul Maruff, PhD^{6,7}, David A. Balota, PhD^{1,2,4}, John C. Morris, MD^{1,4}, Randall J. Bateman, MD^{1,3,4}, & The Dominantly Inherited Alzheimer Network-Trials Unit.

(1) Department of Neurology, Washington University School of Medicine, St. Louis, MO USA; (2) Department of Psychological & Brain Sciences, Washington University in St. Louis, St. Louis, MO USA; (3) The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), Washington University School of Medicine, St. Louis, MO USA; (4) Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO USA; (5) Department of Human Development and Family Studies, Pennsylvania State University, State College, PA USA; (6) The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia; (7) Cogstate Ltd, Melbourne, Victoria, Australia

OC36 - Associating Cognitive Functioning Profiles with Amyloid Status in ADNI2, with Implications for Adaptive Screening for Amyloid

Sarah J Carr PhD¹, Judith Jaeger PhD^{2,3}, Nancy Maserejian ScD⁴, Ahmed Enayatallah⁴, Alan Lerner^{1,5}, Yanming Wang⁶, Sheng Yang⁷, Wenting Wang⁴, Shijia Biang⁴, Curtis Tatsuoka PhD^{1,5} and for the Alzheimer's Disease Neuroimaging Initiative*

(1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) CognitionMetrics, DE USA; (3) Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY USA; (4) Biogen, Cambridge, MA, USA; (5) Neurological Institute, University Hospitals Case Medical Center, Beachwood, OH USA; (6) Department of Radiology, Case Western Reserve University, Cleveland, OH USA; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

OC37 - Alzheimer's Disease Dementia and the Long-Term Impact on Caregiver Burden – 36-Month results from GERAS

Catherine Reed, PhD¹, Mark Belger, BSc¹, J. Scott Andrews, PharmD², Antje Tockhorn-Heidenreich, MSc¹.

(1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly and Company, Indianapolis, IN, USA

OC38 - Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid A β 25-35 Peptide-Induced Toxicity in Mice.

Guillaume J. Blivet, MS¹, Johann Meunier, PhD², Francois J. Roman, PhD², Jacques Touchon, MD, PhD^{3,4}

(1) REGENLIFE SAS, Montpellier, France; (2) Amylgen SAS, Montferrier-sur-Lez, France; (3) INSERM UI061, Montpellier, France (4) University of Montpellier, France

3:15 – 4:15 p.m.

Late Breaking Oral Communications

4:15 – 4:30 p.m.

Closing Session

REGISTRATION

Early bird fees (until September 1)

1. Regular Registration (no lunches) **895€** - Regular registration (with 3 lunches) **1024€**
2. EADC Member registration (no lunches) **704€** - Regular registration (with 3 lunches) **833€**
(to benefit from this rate you must be an active member of the European Disease Consortium)

Full registration fees (After September 2)

1. Regular Registration (no lunches) **1027€** - Regular registration (with 3 lunches) **1156€**
2. EADC Member registration (no lunches) **854€** - EADC Member registration (with 3 lunches) **983€**
(to benefit from this rate you must be an active member of the European Disease Consortium)

Please note that registration to CTAD 2017 includes :
access to all conference sessions, attendee bag, one-year online subscription to the Journal of Prevention of Alzheimer's Disease (JPAD) and CTAD abstracts

You can register directly on our website www.ctad-alzheimer.com

ACCOMMODATIONS



Book your accommodation at the Conference Venue

This year again CTAD has negotiated a special price to stay at the Boston Park Plaza where CTAD will be held.

Boston Park Plaza
50 Park Plaza at Arlington Street
Boston, MA 02116-3912

- The price for a single room is **279\$** (including breakfast)
- The price for a double room is **319\$** (including breakfast for 2 people)

Make sure you book your room early on to ensure you stay at the conference venue.

Book your room on our website www.ctad-alzheimer.com



Clinical Trials on Alzheimer's Disease

Get in touch

CTAD BOSTON 2017

CTAD Congress

Phone: +33 4 67 10 92 23

Email: ctad@ant-congres.com

www.ctad-alzheimer.com

Follow us on



@CTAD2017



CTAD Alzheimer



CTAD Conference

#CTAD2017

www.ctad-alzheimer.com